Every material Form 8-K Linde filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Linde plc reported third-quarter 2026 sales of $9.4 billion, representing a 9% increase year-over-year, alongside net income of $1,692 million and diluted EPS of $3.66. On an adjusted basis, operating profit reached $2.8 billion and adjusted diluted EPS rose 9% to $4.59, while management updated full-year 2026 adjusted EPS guidance to a range of $17.82 to $17.92.
Third-quarter 2026 sales reached $9.4 billion, up 9% year-over-year, with underlying sales growing 5%.
Adjusted diluted earnings per share for the quarter were $4.59, up 9% compared to the prior-year period.
Operating cash flow for the quarter was $3.2 billion, an increase of 8% year-over-year.
Full-year 2026 adjusted diluted EPS guidance was set at $17.82 to $17.92.
Linde plc reported second-quarter 2026 sales of $9.3 billion, up 9% from a year earlier, and GAAP diluted EPS of $4.15, up 11%. The company also guided to full-year 2026 adjusted EPS of $17.70 to $17.90, representing 8% to 9% growth, which signals continued earnings growth for shareholders although operating margin fell 60 basis points.
Q2 2026 sales were $9,289 million, up 9%, with underlying sales up 4% from 2% price and 2% volume
Adjusted EPS was $4.50, up 10%; GAAP diluted EPS was $4.15, up 11%
Full-year 2026 adjusted EPS guidance is $17.70 to $17.90; third-quarter guidance is $4.45 to $4.55
Operating margin was 27.5% and adjusted operating margin 29.5%, with operating margin 60 basis points lower than the prior year
Linde plc issued three series of euro-denominated notes on May 13, 2026, totaling €1.6 billion in net proceeds after manager fees. The company said the proceeds will fund general corporate purposes, and the filing describes a new issuance under its €25 billion European debt program.
Issued €600 million Floating Rate Notes due 2028, €500 million 3.200% Notes due 2030 and €500 million 3.800% Notes due 2036
Net proceeds of approximately €1,595 million after fees to the managers, before other offering expenses
Notes were admitted to the Luxembourg Stock Exchange, and the program base prospectus is dated May 4, 2026
Linde reported first-quarter 2026 sales of $8.8 billion, up 8% from a year earlier, and diluted EPS of $3.98, up 13%. The company also projected full-year 2026 adjusted EPS of $17.60 to $17.90, which it says is 7% to 9% growth, and second-quarter adjusted EPS of $4.40 to $4.50.
Q1 2026 sales $8.8 billion, up 8%; underlying sales up 3%
Reported diluted EPS $3.98, up 13%; adjusted EPS $4.33, up 10%
Adjusted operating margin 30.0%, down 10 basis points year over year
Linde reported fourth-quarter 2025 sales of $8,764 million, up 6%, and adjusted EPS of $4.20, up 6%, while GAAP diluted EPS fell 9% to $3.26 and net income fell 11% to $1,530 million. The company guided 2026 adjusted diluted EPS to $17.40 to $17.90, up 6% to 9%, which gives shareholders a forward profit range but also highlights a gap between adjusted and GAAP results.
Q4 2025 sales $8,764 million, up 6%; underlying sales up 3%
Q4 2025 GAAP diluted EPS $3.26, down 9%; adjusted EPS $4.20, up 6%
2026 full-year adjusted EPS guidance $17.40 to $17.90; Q1 2026 guidance $4.20 to $4.30
Full-year 2025 returned $7.4 billion to shareholders through dividends and share repurchases
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Linde filing is on SEC EDGAR ↗. 8-K briefs of other companies →